Go with the Flow—Early Assessment of Measurable Residual Disease in Children with Acute Lymphoblastic Leukemia Treated According to ALL IC-BFM2009
Authors:
- Katarzyna Pawinska-WasikowskaKPKatarzyna Pawinska-Wasikowska
- Karolina Bukowska-StrakovaKBKarolina Bukowska-Strakova
- Marta SurmanMSMarta Surman
- Monika RygielskaMRMonika Rygielska
- Beata SadowskaBSBeata Sadowska
- Teofila KsiazekTKTeofila Ksiazek
- Tomasz KlekawkaTKTomasz Klekawka
- Aleksandra WieczorekAWAleksandra Wieczorek
- Szymon SkoczenSSSzymon Skoczen
- Walentyna BalwierzWBWalentyna Balwierz
Open Access
Abstract
Measurable residual disease (MRD) is a well-known tool for the evaluation of the early response to treatment in patients with acute lymphoblastic leukemia (ALL). In respect to predicting the relapse the most informative cut-off and time point of MRD measurement during therapy were evaluated in our study. Between 1 January 2013 and 31 December 2019, multiparametric flow cytometry (MFC) MRD was measured in the bone marrow of 140 children with ALL treated according to the ALL IC-BFM2009 protocol. The MRD cut-off of 0.1% and day 33, end of induction, were the most discriminatory for all patients. Patients with negative MRD on day 15 and 33 had a higher 5-year overall survival—OS (100%) and a higher relapse-free survival—RFS rate (97.6%) than those with positive levels of MRD (≥0.01%) at both time points (77.8% and 55.6%, p = 0.002 and 0.001, respectively). Most patients with residual disease below 0.1% on day 15 exhibit hyperdiploidy or ETV6-RUNX1 in ALL cells. Measurement of MRD at early time points can be used with simplified genetic analysis to better identify low and high-risk patients, allowing personalized therapies and further improvement in outcomes in pediatric ALL.Keywords
This publication has 36 references indexed in Scilit:
- Detection of minimal residual disease in pediatric acute lymphoblastic leukemiaCytometry Part B: Clinical Cytometry, 2013
- Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 studyBlood, 2010
- Modulation of antigen expression in B‐cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug‐induced regulatory phenomenon. Results of the AIEOP‐BFM‐ALL‐FLOW‐MRD‐Study GroupCytometry Part B: Clinical Cytometry, 2010
- Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemiaLeukemia, 2009
- Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone MarrowJournal of Clinical Oncology, 2009
- Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)Blood, 2009
- Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after inductionLeukemia, 2008
- Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group studyBlood, 2008
- A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcomeBlood, 2006
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998